PRINCETON, N.J., March 28, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the European Association for the Study of the Liver (EASL) on Saturday, April 2, 2011 starting at 8:00pm CET. During this webcast, management will review Pharmasset's progress on the programs that are the subject of presentations at EASL.

To access a simultaneous webcast of this event via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

PSI-7977

Abstract (oral)

"Once Daily PSI-7977 plus PegIFN/RBV: Rapid Virologic Suppression in Treatment Naive Patients with HCV GT2/GT3 in a Phase 2b Trial" will be presented in the HCV Drug Development session on Friday, April 1 at 4:15pm CET. Authors of the study are Lalezari, J. et al.

Abstract 1372

"Once Daily PSI-7977 Plus Peg-IFN/RBV in HCV GT1: 98% Rapid Virologic Response, Complete Early Virologic Response: The PROTON Study" will be presented in a late breaker poster session on Thursday, March 31. Authors of the study are Nelson, DR. et al.

PSI-938

Abstract 1235

"PSI-352938, A Novel Purine Nucleotide Analog, Exhibits Potent Antiviral Activity and No Evidence of Resistance in Patients With HCV Genotype 1 Over 7 Days" will be presented in a poster session on Saturday, April 2. Authors of the study are Rodriguez-Torres M. et al.

Abstract 1217

"Mechanism of HCV Replicon Resistance to PSI-352938, a Cy

'/>"/>

SOURCE